MEDX Stock Forecast 2025-2026
Distance to MEDX Price Targets
MEDX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Horizon ETF (MEDX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MEDX and similar high-potential opportunities.
Latest MEDX Stock Price Targets & Analyst Predictions
MEDX has shown a year-to-date change of -0.2% and a 1-year change of -5.2%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for MEDX. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MEDX Analyst Ratings
MEDX Price Target Range
Latest MEDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MEDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 22, 2022 | Truist Securities | Hold | Maintains | $0.00 | |
| Nov 23, 2021 | HSBC | Hold | Initiates | $0.00 | |
| Nov 17, 2021 | RBC Capital | Sector Perform | Maintains | $0.00 | |
| Nov 11, 2021 | Jefferies | Hold | Upgrade | $0.00 | |
| May 21, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $0.00 | |
| May 11, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $0.00 | |
| Apr 13, 2020 | SunTrust Robinson Humphrey | Buy | Maintains | $0.00 | |
| Feb 21, 2020 | CFRA | Buy | Upgrade | $0.00 | |
| Jan 21, 2020 | Jefferies | Buy | Upgrade | $0.00 | |
| Oct 23, 2019 | Redburn | Neutral | Downgrade | $0.00 | |
| Aug 1, 2019 | BTIG | Neutral | Downgrade | $0.00 | |
| Jun 20, 2019 | Barclays | Overweight | Upgrade | $0.00 | |
| Oct 26, 2018 | UBS | Buy | Upgrade | $0.00 | |
| Oct 18, 2018 | DZ Bank | Hold | Downgrade | $0.00 | |
| Aug 28, 2018 | HSBC | Buy | Upgrade | $0.00 | |
| Apr 24, 2018 | Deutsche Bank | Buy | Upgrade | $0.00 | |
| Mar 17, 2016 | Nomura | Buy | Initiates | $0.00 | |
| Jan 5, 2016 | UBS | Buy | Upgrade | $0.00 | |
| Oct 30, 2015 | SunTrust Robinson Humphrey | Buy | Maintains | $0.00 | |
| Oct 30, 2015 | PiperJaffray | Neutral | Maintains | $0.00 |
Horizon Kinetics Medical ETF (MEDX) Competitors
The following stocks are similar to Horizon ETF based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Horizon Kinetics Medical ETF (MEDX) Financial Data
Horizon Kinetics Medical ETF has a market capitalization of $15.06B with a P/E ratio of 25.3x. The company generates $17.62B in trailing twelve-month revenue with a 28.8% profit margin.
Revenue growth is +7.1% quarter-over-quarter, while maintaining an operating margin of +10.9% and return on equity of +9.9%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Horizon Kinetics Medical ETF (MEDX) Business Model
About Horizon Kinetics Medical ETF
Provides exposure to the healthcare sector.
The ETF generates revenue by investing in a diversified portfolio of companies involved in healthcare, including biotechnology, pharmaceuticals, and medical devices. It aims to capitalize on the growth of innovative firms leading advancements in medical research and technology.
Horizon Kinetics Medical ETF is managed by Horizon Kinetics, a firm recognized for its analytical investment strategies. This ETF allows investors to participate in the healthcare industry's growth without the need to individually select stocks, offering a simplified investment approach.
Horizon Kinetics Medical ETF (MEDX) Latest News & Analysis
Latest News
Eli Lilly (LLY) has raised its 2024 outlook due to increasing sales of its obesity drug Zepbound and diabetes treatment Mounjaro.
Eli Lilly's raised outlook signals strong sales growth potential, enhancing investor confidence and possibly driving stock prices higher due to increased revenue expectations.
Eli Lilly (LLY) reported strong Q4 2023 earnings, surpassing estimates due to robust sales of diabetes and weight-loss treatments.
Eli Lilly's strong Q4 2023 earnings and sales growth in diabetes and weight-loss treatments indicate robust demand, potentially boosting stock performance and investor confidence.
Eli Lilly Beats on Q3 Earnings: ETFs to Buy
1 year agoEli Lilly (LLY) reported strong Q3 2023 earnings, exceeding estimates for revenue and profit, with continued strong performance from its Mounjaro anti-obesity drug.
Eli Lilly's strong earnings and Mounjaro's success signal robust growth potential, likely boosting investor confidence and stock performance.
Eli Lilly (LLY) saw its stock price surge significantly after a strong Q2 2023 earnings report and positive outlook, making related ETFs attractive for investors.
Eli Lilly's stock surge reflects strong earnings and a positive outlook, signaling robust growth potential. ETFs with significant exposure could capitalize on this momentum for better returns.
Eli Lilly (LLY) will acquire DICE Therapeutics (DICE) for about $2.4 billion to enhance its immunology pipeline focused on immune disease treatments.
Eli Lilly's $2.4 billion acquisition of DICE Therapeutics enhances its immunology portfolio, potentially driving future growth and impacting stock performance positively.
The FDA has recommended Pfizer, Moderna, and Novavax to create single-strain vaccines targeting the omicron subvariant XBB.1.5, potentially benefiting biotech ETFs.
The FDA's recommendation for updated vaccines may boost biotech ETFs tied to Pfizer, Moderna, and Novavax, potentially driving stock prices higher as demand for vaccines increases.
Frequently Asked Questions About MEDX Stock
What is Horizon Kinetics Medical ETF's (MEDX) stock forecast for 2025?
Analyst forecasts for Horizon Kinetics Medical ETF (MEDX) are not currently available. The stock is trading at $26.09.
Is MEDX stock a good investment in 2025?
Analyst ratings for MEDX are not currently available. The stock is currently trading at $26.09. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MEDX stock?
Price predictions from Wall Street analysts for MEDX are not currently available. The stock is trading at $26.09.
What is Horizon Kinetics Medical ETF's business model?
The ETF generates revenue by investing in a diversified portfolio of companies involved in healthcare, including biotechnology, pharmaceuticals, and medical devices. It aims to capitalize on the growth of innovative firms leading advancements in medical research and technology.
What is the highest forecasted price for MEDX Horizon Kinetics Medical ETF?
Price targets from Wall Street analysts for MEDX are not currently available. The stock is trading at $26.09.
What is the lowest forecasted price for MEDX Horizon Kinetics Medical ETF?
Price targets from Wall Street analysts for MEDX are not currently available. The stock is trading at $26.09.
What is the overall MEDX consensus from analysts for Horizon Kinetics Medical ETF?
Analyst ratings for MEDX are not currently available. The stock is trading at $26.09.
How accurate are MEDX stock price projections?
Stock price projections, including those for Horizon Kinetics Medical ETF, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.